GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (NAS:MRNA) » Definitions » Earnings Yield (Joel Greenblatt) %

Moderna (Moderna) Earnings Yield (Joel Greenblatt) %

: -12.74% (As of Dec. 2023)
View and export this data going back to 2018. Start your Free Trial

Moderna's Enterprise Value for the quarter that ended in Dec. 2023 was $30,629 Mil. Moderna's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-3,904 Mil. Moderna's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -12.74%.

The historical rank and industry rank for Moderna's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

MRNA' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -15.32   Med: -1.37   Max: 36.16
Current: -12.41

During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of Moderna was 36.16%. The lowest was -15.32%. And the median was -1.37%.

MRNA's Earnings Yield (Joel Greenblatt) % is ranked better than
55.12% of 1397 companies
in the Biotechnology industry
Industry Median: -15.77 vs MRNA: -12.41

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Moderna's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Moderna Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Moderna's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Premium Member Only Premium Member Only Premium Member Only -9.73 -2.05 14.37 15.90 -12.74

Moderna Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings Yield (Joel Greenblatt) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.90 9.92 2.20 -6.96 -12.74

Competitive Comparison

For the Biotechnology subindustry, Moderna's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moderna Earnings Yield (Joel Greenblatt) % Distribution

For the Biotechnology industry and Healthcare sector, Moderna's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Moderna's Earnings Yield (Joel Greenblatt) % falls into.



Moderna Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Modernas Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-3904/30628.9
=-12.75 %

Moderna's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3,904 Mil.



Moderna  (NAS:MRNA) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Moderna Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Moderna's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Moderna (Moderna) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (NAS:MRNA) » Definitions » Earnings Yield (Joel Greenblatt) %
Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Executives
Stephen Hoge officer: President C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James M Mock officer: Chief Financial Officer 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Shannon Thyme Klinger officer: Chief Legal Officer 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Noubar Afeyan director, 10 percent owner C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Arpa Garay officer: Chief Commercial Officer 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Stephane Bancel director, officer: Chief Executive Officer 320 BENT STREET, CAMBRIDGE MA 02141
Juan Andres officer: See Remarks C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paul Burton officer: Chief Medical Officer 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
David W Meline officer: Chief Financial Officer 3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Jorge M Gomez officer: See Remarks C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Sagan director AKAMAI TECHNOLOGIES INC, 8 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Tal Zvi Zaks officer: Chief Medical Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Lori M. Henderson officer: General Counsel and Secretary MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Le Goff Corinne officer: Chief Commercial Officer 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115

Moderna (Moderna) Headlines

From GuruFocus

Moderna Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Moderna Inc at UBS BioPharma Conference Transcript

By GuruFocus Research 01-23-2024

Moderna Inc Clinical Data Call Transcript

By GuruFocus Research 01-23-2024

Moderna Inc ASCO Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Moderna Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024